Search

CN-121987888-A - Oncology device of dosing

CN121987888ACN 121987888 ACN121987888 ACN 121987888ACN-121987888-A

Abstract

The invention belongs to the technical field of medical equipment, and particularly discloses a oncology drug delivery device which comprises a protective shell and a pressurizing cylinder, wherein the protective shell is fixed on one side of a mounting seat and is arranged from top to bottom, a second piston and a first piston are coaxially and slidably arranged in the pressurizing cylinder from top to bottom, a piston shaft is coaxially fixed on the upper side of the first piston, a piston sleeve is coaxially fixed on the upper side of the second piston, the piston shaft is axially and slidably arranged in a sealing manner to penetrate through the second piston and the piston sleeve, a pressurizing and sealing integrated switching mechanism is arranged in the protective shell, and a liquid control module is connected to the pressurizing cylinder. According to the invention, a crank shaft assembly is driven by a motor, a linkage mode of a piston is switched by a knob, continuous pressurization and drug delivery are realized by matching the relative reciprocating motion of double pistons with a one-way valve, then the single piston is locked to only enable the other piston to move, a pulse wash pipe for unidirectional intermittent liquid injection is realized, and a needle is pulled out in a positive pressure compensation volume in a liquid pressing stroke, so that the integration of continuous drug delivery and the pulse wash pipe is realized, the needle pulling backflow is avoided, and the operation is convenient.

Inventors

  • MENG XIAOMIN
  • LIU AIHUA
  • LI NA
  • LI JIANAN
  • YANG LUXIA
  • ZHOU XINYU

Assignees

  • 中国人民解放军总医院第二医学中心

Dates

Publication Date
20260508
Application Date
20260402

Claims (8)

  1. 1. The oncology drug delivery device comprises a mounting seat (1) fixedly arranged, a protective shell (2) and a pressurizing cylinder (3) which are fixedly arranged on one side of the mounting seat (1) and are arranged from top to bottom, and is characterized in that a second piston (5) and a first piston (4) are coaxially and slidably arranged in the pressurizing cylinder (3) from top to bottom, a piston shaft (41) is coaxially and fixedly arranged on the upper side of the first piston (4), a piston sleeve (51) is coaxially and fixedly arranged on the upper side of the second piston (5), the piston shaft (41) penetrates through the second piston (5) and the piston sleeve (51) in a sealing and sliding manner upwards, a liquid supply pipe (31) is laterally communicated with the pressurizing cylinder (3) at a position between the second piston (5) and the first piston (4), and a liquid outlet pipe (31) is communicated with the bottom of the pressurizing cylinder (3); The pressure-punching-sealing integrated switching mechanism (6) is arranged in the protective shell (2), and the pressure cylinder (3) is connected with the liquid control module (7); The pressurization punching integrated switching mechanism (6) comprises two crankshaft assemblies (61) symmetrically arranged in the protective shell (2), a switchable connecting assembly (62) connected with the piston sleeve (51) and the piston shaft (41), and a synchronous driving assembly (63) for driving the crankshaft assemblies (61) and the switchable connecting assembly (62) to synchronously and symmetrically move.
  2. 2. The oncology drug delivery device according to claim 1, wherein each crank assembly (61) comprises a main shaft (611) with two ends rotatably connected with the protective housing (2) and two bellcrank levers (612) arranged on the main shaft (611), wherein the two bellcrank levers (612) on the same main shaft (611) are arranged 180 degrees opposite to each other.
  3. 3. The oncology drug delivery device according to claim 2, wherein the switchable connecting assembly (62) comprises a first cross rod (621) symmetrically arranged at two sides of the upper part of the piston sleeve (51), a sliding sleeve (622) sliding and sleeved on the upper part of the piston shaft (41), and a second cross rod (623) symmetrically arranged at two sides of the sliding sleeve (622), wherein the second cross rod (623) is arranged above the first cross rod (621), and in the two crank assemblies (61), two symmetrically distributed cranks (612) with the same position are respectively connected with the two first cross rods (621) in a rotating way through connecting rods (624) which are arranged in a rotating way, and the other two symmetrically distributed cranks (612) are respectively connected with the two second cross rods (623) in a rotating way through connecting rods (624) which are arranged in a rotating way.
  4. 4. A oncology drug delivery device according to claim 3 wherein the switchable coupling assembly (62) further comprises a fixing sleeve (626) fixed on the protective housing (2), the piston shaft (41) extends upwardly out of the fixing sleeve (626), a first knob (625) capable of abutting against the piston shaft (41) is threaded through the sliding sleeve (622), and a second knob (627) capable of abutting against the piston shaft (41) is threaded through the fixing sleeve (626).
  5. 5. A oncology drug delivery device according to claim 4 wherein the synchronous drive assembly (63) comprises two gears (632) coaxially fixed to the two spindles (611) respectively and engaged with each other, and a servo motor (631) fixed to the protective housing (2) and adapted to drive one of the spindles (611) to rotate, so as to drive the two spindles (611) to rotate symmetrically and inversely.
  6. 6. The oncology drug delivery device according to claim 5, wherein the liquid control module (7) comprises a first one-way valve (71), a second one-way valve (72) and a third one-way valve (73), the first one-way valve (71) is arranged at the joint of the liquid supply pipe (33) and the pressurizing cylinder (3), the one-way circulation direction of the first one-way valve is from the liquid supply pipe (33) to the pressurizing cylinder (3), the second one-way valve (72) is arranged on the first piston (4) in a penetrating way, the one-way circulation direction of the second one-way valve is from the second piston (5) to the liquid outlet pipe (31), and the third one-way valve (73) is arranged at the joint of the liquid outlet pipe (31) and the pressurizing cylinder (3), and the one-way circulation direction of the third one-way valve is from the pressurizing cylinder (3) to the liquid outlet pipe (31).
  7. 7. A oncology drug delivery device as claimed in claim 6 wherein the control program of the servo motor (631) is set to a final integer number of turns each time the servo motor (631) is shut down such that the first piston (4) and the second piston (5) are in initial extreme symmetric positions each time the servo motor is stopped.
  8. 8. The oncology drug delivery device according to claim 7, wherein the tail end of the liquid outlet pipe (31) is communicated with a puncture needle (32), and the protective shell (2) is provided with an operation port (21) at a position opposite to the movable range of the first knob (625).

Description

Oncology device of dosing Technical Field The invention belongs to the technical field of medical equipment, and particularly relates to a oncology drug delivery device. Background In the field of clinical treatment of tumors, implanted intravenous ports are commonly used as medical devices for establishing long-term vascular access for long-term intravenous chemotherapy, targeted drug delivery, and nutritional support. In conventional administration procedures, it is often necessary to maintain continuous, stable infusion of the drug solution by means of an external pressurizing device such as an infusion pump. After the single administration procedure is completed, the infusion port and the in-vivo catheter must be subjected to standard flushing and sealing operations in order to maintain the patency of the catheter and prevent the drug residue from crystallizing or blood coagulation. However, the existing oncology administration and tube sealing device and operation procedure still have defects in practical clinical application: in the administration phase, it is generally necessary to continuously pressurize in order to ensure a smooth concentration of the drug, while in the washpipe phase, in order to effectively strip and remove the drug residues or fibrin sheaths adhering to the inner wall of the catheter, a "pulsed" washpipe technique (i.e., intermittent positive pressure injection) must be employed to artificially create fluid turbulence inside the catheter. In the prior art, conventional pressurized drug delivery devices (e.g., electronic infusion pumps) only provide continuous pressurization and are not directly compatible with the fluid output requirements of impulse washpipes. Therefore, the clinical operation often needs to adopt a separated operation, namely, continuous administration is finished by using an infusion pump, then the administration pump is removed, and then a medical staff manually uses a syringe to perform pulse type flushing. Such split operation adds additional workload to the healthcare worker and the pressure peaks and frequency of the manual pulse tube are extremely dependent on the experience of the operator, making standardization difficult. In the tube sealing stage, a tube sealing liquid such as heparin saline is usually injected into the transfusion port seat cavity and the intravenous catheter to form an anticoagulated isobaric or positive pressure environment. However, the puncture diaphragm at the top of the conventional transfusion port is usually made of high-molecular elastic silica gel material. When the tube sealing operation is finished and the nondestructive puncture needle is pulled out, the puncture membrane can outwards bulge and deform due to friction force between the surface of the needle body and the elastic membrane, so that the volume of the cavity in the transfusion port seat is instantaneously increased, instantaneous negative pressure is generated in the closed catheter system, and further, the venous blood at the far end is sucked to flow back into the tail end of the catheter, and the phenomenon of needle pulling back occurs. Although the elastic diaphragm rebounds to reset after needle withdrawal and generates certain positive pressure compensation, the pressure gradient generated by the rebound of the diaphragm is often insufficient to fully re-press the withdrawn blood back to the blood vessel due to the viscosity and diffusivity of the blood, and the residual blood remained at the tail end of the catheter is extremely easy to coagulate, so that thrombotic obstruction of the tube is caused, and clinical risks are increased. Disclosure of Invention According to the oncology drug delivery device, the crank shaft assembly is driven by the motor, the linkage mode of the piston is switched by the knob, continuous pressurization drug delivery is realized by the aid of the reciprocating motion of the double pistons relative to each other and the one-way valve, then the single piston is locked to only enable the other piston to move, the pulse flushing pipe for unidirectional intermittent liquid injection is realized, the positive pressure compensation volume is used for drawing out the needle in the liquid pressing stroke, and therefore the integration of continuous drug delivery and the pulse flushing pipe is realized, the back flow of the needle drawing is avoided, and the operation is convenient. The technical scheme includes that the oncology drug delivery device comprises a fixed mounting seat, a protective shell and a pressurizing cylinder, wherein the protective shell and the pressurizing cylinder are fixed on one side of the mounting seat and are arranged from top to bottom, a second piston and a first piston are coaxially and slidably arranged in the pressurizing cylinder from top to bottom, a piston shaft is coaxially fixed on the upper side of the first piston, a piston sleeve is coaxially fixed on the upper side of the second piston, t